BioMarin Tests FDASIA’s Pediatric Voucher Waters With Vimizim Approval

FDA clearance of the Morquio A syndrome treatment provides some insight into how the agency is implementing the 2012 priority review voucher program aimed at incentivizing development of treatments for rare pediatric diseases.